Ionis Pharmaceuticals received FDA approval for Dawnzera (donidalorsen), an antisense therapy to prevent attacks in hereditary angioedema (HAE). The approval followed positive phase III trial results demonstrating significant reduction in swelling episodes compared to placebo, including in patients switching from existing treatments. Dawnzera offers an autoinjector with dosing intervals potentially extending to eight weeks, competing in a market with preexisting HAE therapies.